Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesBeginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

BioCorRx (BICX) Short-Term Debt repayments (2012 - 2014)

BioCorRx recorded quarterly Short-Term Debt repayments of -$26060.0 in Q4 2014, down 53.29% quarter-over-quarter from -$17000.0 in Q3 2014, and up 27.61% year-over-year from -$20421.4 in Q4 2013.

BioCorRx's Short-Term Debt repayments history runs 3 years deep, the most recent figure standing at -$26060.0 for Q4 2014.

  • In Q4 2014, Short-Term Debt repayments rose 27.61% year-over-year to -$26060.0; the TTM figure through Dec 2014 stood at -$131296.0 (down 84.73% YoY), while the FY2015 annual figure was -$28000.0, up 78.67% from the prior year.
  • Short-Term Debt repayments came in at -$26060.0 for Q4 2014 at BioCorRx, down from -$17000.0 in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of -$3374.0 in Q3 2012 to a low of -$80736.0 in Q2 2014.
  • A 3-year average of -$23507.3 and a median of -$18353.5 in 2012 frame the typical range for Short-Term Debt repayments.
  • Across the five-year window, Short-Term Debt repayments slumped 227.27% in 2013 and jumped 63.77% in 2014, its largest moves.
  • BioCorRx's Short-Term Debt repayments stood at -$11000.0 in 2012, then plunged by 227.27% to -$36000.0 in 2013, then rose by 27.61% to -$26060.0 in 2014.
  • According to Business Quant data, Short-Term Debt repayments over the past three periods registered -$26060.0, -$17000.0, and -$80736.0 for Q4 2014, Q3 2014, and Q2 2014 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 HCA Healthcare 84.64 Bn 87.02 Bn 16.26 Bn -
2 Tenet Healthcare 15.22 Bn 14.39 Bn 4.41 Bn -
3 Davita 13.10 Bn 13.96 Bn 1.07 Bn -
4 Encompass Health 10.50 Bn 11.12 Bn 1.34 Bn -
5 Ensign 9.69 Bn 9.09 Bn 293.37 Mn -
6 Universal Health Services 8.92 Bn 8.88 Bn 3.21 Bn -
7 Fresenius Medical Care AG 7.31 Bn 4.93 Bn 22,843.10 Bn -
8 Chemed 5.83 Bn 5.81 Bn 215.76 Mn -
9 Pacs 5.76 Bn 5.51 Bn 345.96 Mn 100.00 Mn
10 BioCorRx - - 189,355.00 -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2014 -26,060.00
Dec 31, 2014 -26,060.00
Sep 30, 2014 -17,000.00
Sep 30, 2014 -17,000.00
Jun 30, 2014 -80,736.00
Jun 30, 2014 -80,736.00
Mar 31, 2014 -7,500.00
Mar 31, 2014 -7,500.00
Dec 31, 2013 -36,000.00
Dec 31, 2013 -36,000.00
Mar 31, 2013 -20,700.00
Mar 31, 2013 -20,700.00
Dec 31, 2012 94,077.00
Dec 31, 2012 94,077.00
Sep 30, 2012 -3,374.00
Sep 30, 2012 -3,374.00
Jun 30, 2012 -19,707.00
Jun 30, 2012 -19,707.00
Mar 31, 2012 -12,996.00
Mar 31, 2012 -12,996.00